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Oral and Oropharyngeal cancer: 
increasing salivary Flow with 
Tasteless sugar-free chewing gum
r 
Julie Killerup Kaae , Lone Stenfeldt and Jesper Grau Eriksen*
Department of Oncology, Odense University Hospital, Odense, Denmark
introduction: Radiation-induced xerostomia is a frequent late side effect after treatment 
for oral and oropharyngeal cancers. This may induce swallowing difficulties, compro-
mised oral well-being, reduced nutrition intake, or speech deficiencies. Consequently, 
quality of life is often impaired for these patients.
Objectives: The purpose of this study was to investigate the possibility to mechanically 
stimulate residual saliva function by using tasteless and sugar-free chewing gum. It was 
hypothesized that tasteless and sugar-free chewing gum could immediately increase 
salivary flow and potentially improve oral well-being when used on a regular basis.
Methods: From October to December 2014, 31 consecutive patients treated with primary 
radiotherapy (RT) and concomitant cisplatin (in locally advanced cases) for oral or oropharyn-
geal cancer consented to participate. All patients had finalized RT 2–8 months prior to partic-
ipation and suffered from xerostomia. Samples of unstimulated and chewing gum-stimulated 
saliva were obtained at the entry into the study (Visit 1). For 2 weeks, patients used chewing 
gum on a regular basis whereupon saliva measurements were repeated to verify the changes 
(Visit 2). An abbreviated EORTC H&N35 questionnaire was completed for both visits. A small 
control group consisting of young and healthy individuals also tested the chewing gum.
results: Twenty patients completed the study and an increase in saliva flow was 
observed for 14 patients. Before and after intervention with chewing gum, an increase in 
mean saliva output was seen between unstimulated and stimulated saliva for both Visit 
1 and 2 (p = 0.008 and p = 0.05, respectively). No change in saliva output was seen in 
the control group.
conclusion: The chewing gum was able to stimulate saliva output that was seen at 
the beginning and at the end of the intervention. No improvement in baseline saliva was 
seen. Relevant changes in subjective measures of xerostomia were seen after 2 weeks 
of chewing the gum.
Keywords: xerostomia, chewing gum, radiotherapy, oral cancer, oropharyngeal cancer
inTrODUcTiOn
Xerostomia is a common acute and late side effect when treating head and neck cancer (HNC) 
patients with curative intended radiotherapy (RT) (1–3). Xerostomia is the subjective feeling of oral 
dryness, whereas hyposalivation is the physiological reduction in salivary flow (4). Hyposalivation 
is defined as unstimulated whole saliva flow of ≤0.2 mL/min, and symptoms of xerostomia often 
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become evident when saliva flow is below 0.1–0.2 mL/min (5, 6). 
Xerostomia is not necessarily correlated to a reduction in saliva 
flow and may also be present independent of hyposalivation. 
Healthy individuals produce between 0.5 and 1.5 L of saliva daily, 
with saliva being secreted by the three paired major salivary 
glands. It consists of approximately 99% water and 1% proteins 
and salt, and normal daily secretion of saliva is vital for main-
taining good oral health, nutritional intake, and communication 
skills (7, 8).
The severity of xerostomia caused by RT is affected by the total 
dose and dose per fraction and is often irreversible (9, 10). To 
assess the severity of xerostomia in the clinic, a good approach is 
to make use of an observer-based scoring system, and a validated 
quality of life measurement device and measuring salivary flow 
(11). Various treatments are available to relieve the discomfort of 
xerostomia, including symptomatic relief by oral lubricants and 
saliva substitutes. Salivary stimulants may be considered where 
residual salivary gland function remains (12).
The purpose of this study was to investigate the possibility to 
mechanically stimulate residual saliva function. It was hypoth-
esized that by using a tasteless and sugar-free chewing gum, an 
immediate increase in saliva flow would be obtained and poten-
tially improve oral well-being when used on a regular basis.
MaTerials anD MeThODs
This non-randomized cohort study was conducted at the 
Department of Oncology at Odense University Hospital from 
October to December 2014. HNC patients diagnosed with oral 
or oropharyngeal carcinomas were eligible for participation after 
completing either curative intended treatment with intensity-
modulated radiation therapy (IMRT) or postoperative IMRT 
with or without concomitant cisplatin.
Patients were recruited during follow-up visits to the 
department 2–12  months after having completed treatment. 
Furthermore, all patients had to suffer from xerostomia (slight/
moderate/severe) as graded by the attending physician accord-
ing to the Danish Head and Neck cancer Group (DAHANCA) 
follow-up guidelines. Medical records for all consenting patients 
were reviewed with regard to medication-induced xerostomia.
For each patient, the study consisted of two visits at the depart-
ment separated by 14 days. All oral intakes 1 h before onset of the 
test, which potentially could influence the test results, were not 
recommended. Visit 1 consisted of four elements:
 (1) An unstimulated saliva sample.
 (2) An abbreviated version of the EORTC H&N35 questionnaire.
 (3) Testing the chewing gum.
 (4) A stimulated saliva sample.
First, the unstimulated saliva sample was obtained by the 
patient spitting into a test tube for 5 min. No sipping of water or 
saliva stimulant was allowed 1 h before and during the collection 
of the saliva sample. Second, an abbreviated version of EORTC 
H&N35 questionnaire (including only the oral and food-related 
questions plus two additional questions added for the purpose 
of the study) (Table 2) was completed to asses xerostomia grade, 
quality of life, and difficulties associated with xerostomia (13, 14). 
Afterward, a saliva stimulant in the form of a tasteless sugar-free 
chewing gum was tested and chewed for 5 min supported by a 
metronome (60 beats/min). After depositing the chewing gum, 
the stimulated saliva sample was obtained by the patient spitting 
into a second test tube for 5 min.
The study chewing gum was distributed for use at home in-
between visits, and patients were instructed to use it three to five 
times a day including before regular meals.
At Visit 2, the patient repeated all tests conducted during 
Visit 1. A second unstimulated and stimulated saliva sample was 
obtained, and the EORTC H&N35-abbreviated questionnaire 
was completed again.
chewing gum
For this study, a specially designed chewing gum to stimulate 
whole saliva flow was used. The chewing gum contained neither 
taste nor sugar, had no hard coating, and consisted of a basic 
gum base added mannitol. The chewing gum conformed to the 
relevant European Union legislations on foods. For practical use, 
it was reduced in size to accommodate any inconvenience for 
the recruited patients dealing with pain in the mouth or having 
trouble overcoming large food objects.
control group
To compare and evaluate the saliva stimulating effects of the 
chewing gum, the product was tested on a small control group 
(n =  10) consisting of young, healthy, non-smoking, and non-
medicated students/health-care professionals. None reported 
problems regarding xerostomia. All participants were instructed 
in the spitting and chewing procedures and provided saliva 
samples. One unstimulated and stimulated saliva sample was 
obtained from each participant.
saliva Measurement
Saliva samples were weighted and the salivary flow rate was 
calculated in grams per minute (7). For all sample tubes pre- and 
postweight were measured on a Mettler Toledo (Colombus, OH, 
USA) weight. To determine the exact weight of saliva, the weight 
was calibrated with 500, 100, and 1 g weights before use. After 
weighting, all samples were centrifuged at 2000 × g and 20°C for 
5 min before the volume was determined by use of 3 mL pipettes. 
For this study, the weight of the saliva output was considered most 
accurate.
ethics
Written informed consent was obtained from all patients agree-
ing to participate. The study was approved by the Regional 
Scientific Ethical Committes for Southern Denmark. The study 
was conducted and the data analyzed without involvement from 
Fertin Pharma who produced the chewing gum.
statistics
The primary endpoint was the immediate increase in saliva output 
after stimulation with tasteless sugar-free chewing gum at Visit 1. 
TaBle 1 | Patient and tumor characteristics for all eligible patients.
Totala non-participantsb Participantsc p study groupd pe
n = 62 n = 31 n = 31 n = 20
Men 42 (68%) 18 (58%) 24 (77%) NS 15 (75%) NS
Age (median) (range, years) 63 (39–78) 64 (39–78) 62 (46–73) NS 62 (46–73) NS
Smoking after RT 10 (16%) 9 (29%) 1 (3%) 0.01 0 NS
Follow-up after RT
2–5 months 34 (55%) 18 (58%) 16 (52%) NS 10 (50%) NS
6–9 months 13 (21%) 7 (23%) 6 (19%) 5 (25%)
10–12 months 14 (23%) 7 (23%) 7 (23%) 5 (25%)
>12 months 1 (2%) 1 (3%)
Site
Pharynx 48 (77%) 25 (81%) 23 (79%) NS 15 (75%) NS
Oral cavity 10 (16%) 5 (16%) 5 (16%) 3 (15%)
Saliva gland 1 (2%) 1 (3%) -
Unknown primary tumor 3 (5%) 1 (3%) 2 (7%) 2 (10%)
Clinical stage III–IV 51 (82%) 27 (87%) 24 (77%) NS 16 (80%) NS
Concomitant chemotherapy 32 (52%) 13 (31%) 19 (61%) NS 10 (50%) 0.05
Distance to hospital
>50 km 24 (39%) 12 (36%) 12 (41%) NS 10 (50%) NS
<50 km 38 (61%) 20 (65%) 18 (58%) 10 (50%)
aTotal number of consecutive and eligible patients asked to participated in the study.
bNumber of patients declining to participate including screening failure.
cNumber of patients consenting to participate including patients not completing Visit 2.
dNumber of patients with repeating measurements who complete the study.
ep-Value comparing the patients completing the study with the patients lost to follow up.
RT, radiotherapy; NS, no significant p-value.
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The secondary endpoints included oral well-being estimated by 
the abbreviated EORTC H&N35 questionnaire.
Saliva output was expected to be normally distributed. The 
correlations between measurements of the saliva output were 
tested using a paired t-test. Patient and tumor characteristics 
for all eligible patients and responses to the questionnaires 
were tested by Spearman’s correlation for categorical values. A 
two-sided p-value <0.05 was regarded as significant. Data were 
analyzed using SPSS version 22 for Windows.
resUlTs
A total of 62 consecutive HNC patients were assessed for eligibil-
ity. Thirty-one patients declined participation. Among the 31 
included patients, 11 patients did not complete due to problems 
with prosthetic teeth (n =  2), distance to the hospital (n =  2), 
withdrawal of consent without explanation (n =  5), or screen-
ing failure (n = 2). In total, 20 patients completed the study and 
underwent saliva collection 4 times while testing the chewing 
gum during the 2-week study period.
The study group consisted of 15 men and 5 women, age 
ranging from 46 to 73 years (median 62 years) and all current 
non-smokers. Considering the follow-up period after RT, 10 
patients had completed treatment within 2–5 months, whereas 10 
patients had finished within 6–12 months. The patients declining 
participation did not differ from the group of patients consenting 
to participation with regard to gender, age, follow-up after RT, 
tumor site, clinical stage, or distance to hospital. Only smoking 
tended to be more prominent among patients who did not enter 
the study (p = 0.01) (Table 1).
Xerostomia
All study patients reported xerostomia before testing the chewing 
gum. Responses to the abbreviated EORTC H&N35 questionnaire 
at Visit 1 showed that xerostomia was a major complaint, with 
90% of the patients rating xerostomia as “quite a bit” or “a lot” 
(Table 2). At Visit 2, only 30% of the patients rated xerostomia 
as “quite a bit,” and none experienced complaints corresponding 
to “a lot.” No significant difference was found for the patient-
reported evaluations of xerostomia. Medical records revealed 
that five patients were prescribed opioids, antidepressants, and 
antiepileptic medication, and all five patients had pronounced 
xerostomia complaints (“quite a bite” or “a lot”).
Oral complaints
Pain in the mouth or jaw and eating difficulties were also evalu-
ated with the abbreviated EORTC H&N35 questionnaire before 
and after intervention with the chewing gum (Table 2) and was 
significantly reduced after 2 weeks of intervention (p = 0.05 and 
p =  0.01, respectively). Furthermore, an increase was reported 
in the subjective feeling of total amount of saliva in the mouth 
(p = 0.007). In a total of 19 patients, 95% reported a subjective 
increase in saliva flow after intervention with the chewing gum. 
Eating difficulties in terms of swallowing issues were not found to 
differ significantly, whereas patients reported less trouble enjoy-
ing their meals after Visit 2 (p = 0.004).
salivary Output
Mean distribution and individual data of saliva output for patients 
at Visit 1 are illustrated in Figure 1. At Visit 1, the mean unstimu-
lated saliva output and stimulated saliva output were 0.79 and 
FigUre 2 | Mean output for unstimulated and stimulated saliva 
measured in grams. The blue line represents saliva output at Visit 1 and the 
red line at Visit 2.
FigUre 1 | increase and decrease in saliva output after stimulation 
with the chewing gum (n = 20) from Visit 1. The green line represents an 
increase in saliva output after stimulation. The red line represents a decrease 
or no change. The blue line represents the mean value.
TaBle 2 | responses to the abbreviated eOrTc h&n35 questionnaire from participants completing the study (n = 20).
Visit 1 Visit 2 pa
in the past week have you had… none a little Quite a bit a lot none a little Quite a bit a lot
Oral cavity
Q1 Pain in your mouth? 13 (65%) 4 (20%) 2 (10%)  1 (5%) 17 (85%) 2 (10%) 1 (5%) 0.05
Q2 Pain in your jaw? 14 (70%) 4 (20%) 1 (5%) 1 (5%) 18 (90%) 1 (5%) 1 (5%) 0.01
Q4 A dry mouth? 1 (5%) 1 (5%) 8 (40%) 10 (50%) 7 (35%) 7 (35%) 6 (30%) NS
Q5 Sticky saliva? 4 (20%) 8 (40%) 5 (25%) 3 (15%) 5 (25%) 7 (35%) 7 (35%) 1 (5%) NS
Q6 Less saliva? 7 (35%) 2 (10%) 5 (25%) 6 (30%) 13 (65%) 3 (15%) 3 (15%) 1 (5%) 0.007
eating difficulties
Q7 Problems swallowing liquids? 13 (65%) 6 (30%) 1 (5%) 15 (75%) 4 (20%) 1 (5%) NS
Q8X Problems swallowing solid food? 7 (35%) 5 (25%) 4 (20%) 3 (15%) 6 (30%) 8 (40%) 5 (25%) 1 (5%) NS
Q11 Decreased sense of taste? 8 (40%) 4 (20%) 3 (15%) 5 (25%) 12 (60%) 4 (20%) 3 (15%) 1 (5%) 0.01
Q13 Trouble enjoying your meals? 5 (25%) 3 (15%) 7 (35%) 5 (25%) 6 (30%) 9 (45%) 4 (20%) 1 (5%) 0.004
Q14 Trouble eating with other people? 12 (60%) 4 (20%) 3 (15%) 1 (5%) 10 (50%) 6 (30%) 4 (20%) NS
Q19 Increased saliva flow after using the chewing gum? – – – – “Yes” “No” NS
19 (95%) 1 (5%)
Q6 and Q19 are added questions.
aThe p-value was found by using a paired T-test.
Q is the number of the question in the questionnaire.
XQ8: one response is missing from questionnaire 1.
NS is no significant p-value.
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1.07 g versus 0.62 and 0.82 g at Visit 2 after intervention with the 
chewing gum (Figure 2). The increase in saliva output was found 
to be significant for both Visit 1 and 2 when tested by the two-
sided t-test (p = 0.008 and p = 0.05, respectively). No significant 
difference in stimulated output between Visits 1 and 2 was found 
(p = 0.2). When testing mean saliva flow rate in grams per minute 
(p = 0.05 and p = 0.04) and saliva volume (p = 0.02 and p = 0.05), 
the increase in saliva was also found to be significant.
The mean flow rate for unstimulated saliva was 0.09 mL/min 
after using chewing gum for 2 weeks. The definition for very low 
unstimulated whole saliva flow rate is <0.1 mL/min and corre-
sponds with hyposalivation (6). Looking at all measurements of 
the unstimulated flow rate (milliliters per minute), nine patients 
had a very low flow rate below 0.1 mL/min, and seven patients 
had a low flow rate between 0.1 and 0.2 mL/min.
Saliva output for patients prescribed with xerostomia-induced 
medication (n = 5) did not seem to affect the results of chewing 
gum intervention, with mean unstimulated and stimulated saliva 
output being 1.25 and 1.52 g at Visit 1.
Comparing the mean saliva output from the study group at 
Visit 1 and Visit 2 with the mean saliva output from the control 
group, an increase in saliva production was not seen in the control 
group. For the control group, both mean unstimulated and stimu-
lated saliva output were much higher than the results presented 
in the study group (4.01 and 3.96 g, respectively). No significant 
difference was found between mean unstimulated and stimulated 
saliva output for the control group.
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DiscUssiOn
In this study, HNC patients treated with curative intended RT 
and concomitant chemotherapy had at least 0.2  g increase in 
saliva output after intervention with the tasteless and sugar-free 
chewing gum. For both Visit 1 and Visit 2, saliva output increased 
when stimulated by the chewing gum (p = 0.008 and p = 0.05, 
respectively). This corresponded well with the patients reporting 
a positive subjective change regarding their xerostomia com-
plaint. No special parotid sparing techniques were used for the 
patients included in the study. However, dose constraints to the 
parotid glands [Dmean ≤ 20 Gy (contralateral) or Dmean ≤ 26 Gy 
(both)], submandibular glands (Dmean ≤ 35 Gy), and oral cavity 
(Dmean ≤ 30 Gy) were intended to be met in every single case.
With xerostomia being both an early and late side effect 
to primary curative intended RT for oral and oropharyngeal 
carcinomas, it is common that many patients will experience a 
permanent subjective feeling of dry mouth. Xerostomia is not a 
life-threatening complication; however, decreased saliva flow and 
changes in saliva composition are straining. Saliva often become 
sticky and unmanageable, which compromises oral well-being 
and results in eating difficulties, increased risk of caries, and 
impaired speaking abilities. Living with xerostomia may inflict 
emotional strain such as worry, tension, and depression and limit 
social activities (10, 12, 15).
Various salivary substitutes and stimulants are on the market 
to relieve discomfort associated with xerostomia. Substitutes, 
such as sprays, gels, mouthwashes, and special toothpaste, are 
developed to keep soft tissue moist and increase the viscosity 
of liquids (16). Substitutes are limited by their short duration 
of effect, often unpleasant taste, and high cost but can be useful 
during the night (17). The saliva stimulants include sugar-free 
chewing gum, ascorbic acid (vitamin C tablets), malic acid, and 
pilocarpine (18). There is low level of evidence concerning the 
efficiency of the various products available.
For HNC patients, it remains a challenge to find suitable 
products to increase salivary flow. After ending RT, the oral cavity 
is highly sensitive due to decreased salivary flow rate and altera-
tions to the sense of taste. Strong flavors, such as peppermint or 
lemon, are not favored in the early phase of recovery (19). Sugar 
may contribute to or worsen xerostomia and increases the risk of 
carries. The chewing muscles can be restrained due to radiation 
sequelae, and some patients are confined to processing small food 
items.
The chewing gum designed for this study tries to accommodate 
the need of the HNC patient. The lack of taste serves the purpose 
of stimulating the salivary flow by physical and mechanical 
stimulation alone, whereas the soft texture and small size makes 
it easy to chew regardless of rigid muscles or oral sensitivity. This 
is in agreement with others suggesting that saliva stimulants in 
the form of a sugar-free chewing gum can aid to promote saliva-
tion when residual salivary glandular function remains (20). The 
gum increases salivary flow by stimulating the taste receptors and 
through physical stimulation of the salivary gland (12, 18, 21).
When comparing mean unstimulated and stimulated saliva 
output for both Visit 1 and Visit 2, a relative similar increase in 
salivary output was seen at both visits (Figure 2). The study was 
not able to find an absolute increase in whole unstimulated saliva 
output after the second visit, indicating that 2 weeks of regular 
use of chewing gum did not increase unstimulated saliva output. 
The decline may be explained by the short period of time allotted 
for the patient to adapt to the chewing gum, failure to use it on a 
regular basis, or progressing xerostomia after RT. Furthermore, 
the study from Flink et al. argues that the circadian rhythm and 
fasting may also have a negative impact on the saliva secretion 
in patients with hyposalivation (6). In this study, measurement 
of saliva flow took place throughout the day time with no regard 
to the circadian rhythm of saliva secretion. Due to scheduling 
difficulties, it was not possible to conduct Visit 2 at the exact same 
time slot or location for all study patients.
Despite including 31 eligible HNC patients, only 20 patients 
completed the study. After completing treatment for HNC, the 
patients are only frequenting the department for scheduled 
checkups with a span of 3–6 months. Participating in this study 
required an extra visit to the hospital for saliva collection and 
evaluation of the chewing gum alone. Some of the patients lost to 
follow-up did not allow time for an extra visit due to long travel 
distances or coincide with work.
The study did not look into changes in the saliva composition, 
and further studies should include testing the variations of saliva 
composition. The chewing gum used in this study did not include 
any lubricating or fluoride additives. Further testing ought to 
include chewing gum with emollient additives in order to see 
whether it is possible to make changes in the saliva composition 
and further improve the oral well-being.
cOnclUsiOn
Using chewing gum as a saliva stimulant, the study was able to stim-
ulate and increase mean salivary output for 14 out of 20 consecutive 
HNC patients. The majority of the patients reported a self-rated 
improvement regarding xerostomia complaints and improved oral 
well-being after being subjected to the study chewing gum.
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